Dendritic Cell-Based Cancer Vaccines

[1]  J. Khan,et al.  Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. , 2013, Blood.

[2]  R. Steinman,et al.  CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice. , 2013, Blood.

[3]  A. Godkin,et al.  Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells , 2013, Front. Immunol..

[4]  N. McGovern,et al.  IRF4 Transcription Factor-Dependent CD11b+ Dendritic Cells in Human and Mouse Control Mucosal IL-17 Cytokine Responses , 2013, Immunity.

[5]  D. McNeel,et al.  Monitoring Regulatory Immune Responses in Tumor Immunotherapy Clinical Trials , 2013, Front. Oncol..

[6]  W. Oyen,et al.  Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. , 2013, Cancer research.

[7]  Yulia Nefedova,et al.  Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer , 2012, Nature Immunology.

[8]  P. Kantoff,et al.  Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer , 2012, Cancer Immunology, Immunotherapy.

[9]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[10]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[11]  Hans-Georg Rammensee,et al.  Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. , 2012, Brain : a journal of neurology.

[12]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[13]  S. Biswas,et al.  Characterization of the nature of granulocytic myeloid‐derived suppressor cells in tumor‐bearing mice , 2012, Journal of leukocyte biology.

[14]  Katsuaki Sato,et al.  Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. , 2011, Immunity.

[15]  Yong‐jun Liu,et al.  The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells , 2011, Nature Immunology.

[16]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[17]  P. Schellhammer,et al.  Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer , 2011, Clinical Cancer Research.

[18]  Kristen E. Pauken,et al.  The role of the PD‐1 pathway in autoimmunity and peripheral tolerance , 2011, Annals of the New York Academy of Sciences.

[19]  F. Thistlethwaite,et al.  Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. , 2011, Clinical immunology.

[20]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[21]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[22]  C. Dutertre,et al.  The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8α+ dendritic cells , 2010, The Journal of experimental medicine.

[23]  P. Kloetzel,et al.  Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells , 2010, The Journal of experimental medicine.

[24]  Tomoki Ito,et al.  Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. , 2010, Blood.

[25]  C. Figdor,et al.  Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy , 2010, Cancer Immunology, Immunotherapy.

[26]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[27]  P. Schellhammer,et al.  Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.

[28]  E. Frigimelica,et al.  Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. , 2009, Blood.

[29]  Michelle Collazo,et al.  Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.

[30]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[31]  Gordon D. Brown,et al.  CLEC9A Is a Novel Activation C-type Lectin-like Receptor Expressed on BDCA3+ Dendritic Cells and a Subset of Monocytes , 2008, Journal of Biological Chemistry.

[32]  B. Neyns,et al.  Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  C. Figdor,et al.  Dendritic cell vaccines in melanoma: from promise to proof? , 2008, Critical reviews in oncology/hematology.

[34]  C. Rooney,et al.  Using Dendritic Cell Maturation and IL-12 Producing Capacity as Markers of Function: A Cautionary Tale , 2008, Journal of immunotherapy.

[35]  J. Connolly,et al.  Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I , 2008, Nature Immunology.

[36]  C. Figdor,et al.  Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration , 2008, Cancer Immunology, Immunotherapy.

[37]  P. Lorigan,et al.  Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  F. Locatelli,et al.  Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. , 2007, Blood.

[39]  E. Gilboa.  DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[40]  S. Fox,et al.  Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. , 2007, Cancer immunity.

[41]  C. Liu,et al.  Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells in the Induction of Antigen-Specific Antitumor Immune Responses , 2007, The Journal of Immunology.

[42]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[43]  S. Aamdal,et al.  T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells , 2007, Cancer Immunology, Immunotherapy.

[44]  M. Lesniak,et al.  CD4+CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas , 2007, Journal of Neuro-Oncology.

[45]  M. Joshi,et al.  Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients , 2006, Cancer.

[46]  A. Banham,et al.  CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1 , 2006, The Journal of Immunology.

[47]  S. Aamdal,et al.  Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA , 2006, Cancer Gene Therapy.

[48]  H. Ueno,et al.  Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity , 2006, Journal of immunotherapy.

[49]  L. Old,et al.  Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients , 2006, Journal of immunotherapy.

[50]  M. Ballardini,et al.  Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients , 2006, Journal of Translational Medicine.

[51]  R. Coffman,et al.  Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation , 2006, The Journal of experimental medicine.

[52]  Edgar Schmitt,et al.  Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. , 2006, Blood.

[53]  G. Cheng,et al.  TLR Activation of Langerhans Cell-Like Dendritic Cells Triggers an Antiviral Immune Response1 , 2006, The Journal of Immunology.

[54]  P. Schellhammer,et al.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  W. Oyen,et al.  Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. , 2006, Nuclear medicine and biology.

[56]  L Edler,et al.  Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[58]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[59]  Rong-Fu Wang.  Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. , 2006, Seminars in cancer biology.

[60]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[61]  F. Entschladen,et al.  Tumor immune escape mechanisms: impact of the neuroendocrine system , 2006, Cancer Immunology, Immunotherapy.

[62]  N. Bercovici,et al.  Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate , 2006, Cancer Immunology, Immunotherapy.

[63]  D. Gabrilovich,et al.  Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer , 2006, Cancer Immunology, Immunotherapy.

[64]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  S. Rosenberg,et al.  Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade , 2005, The Journal of Immunology.

[66]  C. Borrebaeck,et al.  Gene Family Clustering Identifies Functionally Associated Subsets of Human In Vivo Blood and Tonsillar Dendritic Cells1 , 2005, The Journal of Immunology.

[67]  C. Heirman,et al.  Dendritic cells differentiated in the presence of IFN‐β and IL‐3 are potent inducers of an antigen‐specific CD8+ T cell response , 2005, Journal of leukocyte biology.

[68]  H. Ueno,et al.  Immune and Clinical Outcomes in Patients with Stage IV Melanoma Vaccinated with Peptide-Pulsed Dendritic Cells Derived From CD34+ Progenitors and Activated with Type I Interferon , 2005, Journal of immunotherapy.

[69]  Francesco Bertoni,et al.  Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells , 2005, Nature Immunology.

[70]  S. Aamdal,et al.  Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination , 2005, Cancer Gene Therapy.

[71]  A. M. Neale,et al.  Results of a phase I study utilizing monocyte‐derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma , 2005, Cancer.

[72]  G. Schuler,et al.  Generation of an Optimized Polyvalent Monocyte-Derived Dendritic Cell Vaccine by Transfecting Defined RNAs after Rather Than before Maturation1 , 2005, The Journal of Immunology.

[73]  C. Figdor,et al.  Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells , 2002, Journal of immunotherapy.

[74]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[75]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[76]  S. Sakaguchi,et al.  CD4+ Tregs and immune control. , 2004, The Journal of clinical investigation.

[77]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[78]  J. Wargo,et al.  Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy , 2004, Journal of immunotherapy.

[79]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[80]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[81]  F. Schmitz,et al.  Herpes simplex virus type-1 induces IFN-α production via Toll-like receptor 9-dependent and -independent pathways , 2004 .

[82]  J. Kirkwood,et al.  Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? , 2004, European journal of cancer.

[83]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[84]  Nina Bhardwaj,et al.  Danger signals: a time and space continuum. , 2004, Trends in molecular medicine.

[85]  F. Brasseur,et al.  Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.

[86]  S. Khoury,et al.  The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. , 2004, Immunity.

[87]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[88]  D. Schadendorf,et al.  Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates , 2004, Cancer Immunology, Immunotherapy.

[89]  Ann Atzberger,et al.  CpG-matured Murine Plasmacytoid Dendritic Cells Are Capable of In Vivo Priming of Functional CD8 T Cell Responses to Endogenous but Not Exogenous Antigens , 2004, The Journal of experimental medicine.

[90]  H. Ueno,et al.  Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. , 2004, Journal of immunological methods.

[91]  C. Sousa.  Activation of dendritic cells: translating innate into adaptive immunity. , 2004 .

[92]  J. Banchereau,et al.  Dendritic cells generated in the presence of GM‐CSF plus IL‐15 prime potent CD8+ Tc1 responses in vivo , 2004, European journal of immunology.

[93]  C. Punt,et al.  Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  S. Menzies,et al.  Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma , 2004, Cancer Immunology, Immunotherapy.

[95]  C. Figdor,et al.  Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[96]  R. Tanaka,et al.  Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial , 2003, British Journal of Cancer.

[97]  A. Yamamoto,et al.  Subcellular Localization of Toll-Like Receptor 3 in Human Dendritic Cells 1 , 2003, The Journal of Immunology.

[98]  Virginia Pascual,et al.  Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. , 2003, Immunity.

[99]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[100]  Matteo Bellone,et al.  Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. , 2003, Cancer research.

[101]  M. Grégoire,et al.  Optimizing dendritic cell–based anticancer immunotherapy: maturation state does have clinical impact , 2003, Cancer Immunology and Immunotherapy.

[102]  A. Aderem,et al.  The Toll-Like Receptor 5 Stimulus Bacterial Flagellin Induces Maturation and Chemokine Production in Human Dendritic Cells1 , 2003, The Journal of Immunology.

[103]  M. Gilliet,et al.  Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. , 2003, Blood.

[104]  J. Köhl,et al.  IL-4 Down-Regulates Anaphylatoxin Receptors in Monocytes and Dendritic Cells and Impairs Anaphylatoxin-Induced Migration In Vivo1 , 2003, The Journal of Immunology.

[105]  R. Elashoff,et al.  Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  M. Gnant,et al.  Dendritic cell-based vaccination in solid cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  W. Oyen,et al.  Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. , 2003, Cancer research.

[108]  K. MacDonald,et al.  Characterization of human blood dendritic cell subsets. , 2002, Blood.

[109]  P. Tam,et al.  Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. , 2002, Cancer research.

[110]  G. Bartsch,et al.  Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  B. Sullenger,et al.  Emerging clinical applications of RNA , 2002, Nature.

[112]  C. Broeckhoven,et al.  mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation , 2002, Leukemia.

[113]  Carsten J. Kirschning,et al.  The Endoplasmic Reticulum-resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-like Receptor 2/4 Pathway* , 2002, The Journal of Biological Chemistry.

[114]  S. Akira,et al.  Interferon-α and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell Subsets , 2002, The Journal of experimental medicine.

[115]  G. Schuler,et al.  Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.

[116]  Michael Rehli,et al.  Novel Signal Transduction Pathway Utilized by Extracellular HSP70 , 2002, The Journal of Biological Chemistry.

[117]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[118]  E. Gilboa,et al.  Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells , 2002, Annals of surgery.

[119]  Michel C. Nussenzweig,et al.  Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[120]  T. Braun,et al.  Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. , 2001, Cancer research.

[121]  T. Giese,et al.  Toll‐like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL‐12 , 2001 .

[122]  N. Kadowaki,et al.  Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.

[123]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[124]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  Y. Liu,et al.  Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity , 2001, Cell.

[126]  A. Enk,et al.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.

[127]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[128]  P. Kalinski,et al.  Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. , 2001, Blood.

[129]  M. Toungouz,et al.  Transient expansion of peptide‐specific lymphocytes producing IFN‐γ after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage‐A1/A3‐positive tumors , 2001, Journal of leukocyte biology.

[130]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[131]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[132]  A. Palucka,et al.  Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells , 2000, The Journal of experimental medicine.

[133]  S. Miltenyi,et al.  BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.

[134]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[135]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[136]  F. Sallusto,et al.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.

[137]  A. Lanzavecchia,et al.  Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization , 2000, Nature Immunology.

[138]  A. Enk,et al.  Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.

[139]  N. Kadowaki,et al.  Natural Interferon α/β–Producing Cells Link Innate and Adaptive Immunity , 2000, The Journal of experimental medicine.

[140]  H. Rammensee,et al.  The heat shock protein gp96 induces maturation of dendritic cells and down‐regulation of its receptor , 2000, European journal of immunology.

[141]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[142]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[143]  W. Scherbaum,et al.  Dendritic cell immunotherapy in disseminated parathyroid carcinoma , 1999, The Lancet.

[144]  P. Ricciardi-Castagnoli,et al.  Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.

[145]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[146]  B. Pulendran,et al.  Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[147]  R. Maldonado-López,et al.  CD8α+ and CD8α− Subclasses of Dendritic Cells Direct the Development of Distinct T Helper Cells In Vivo , 1999, The Journal of experimental medicine.

[148]  M. Toda,et al.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.

[149]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[150]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[151]  A. Enk,et al.  Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.

[152]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[153]  R. Steinman,et al.  The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing , 1995, Nature.

[154]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[155]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[156]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[157]  M. Bevan.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay , 1976, The Journal of experimental medicine.